Jim Simons Lipocine Inc. Transaction History

Renaissance Technologies LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.3 - $0.58 $614 - $1,188	2,049 Added 1.04%	198,349 $63,000
Q4 2022 Feb 13, 2023	SELL	$0.37 - $8.65 $1,147 - $26,815	-3,100 Reduced 1.55%	196,300 $78,000
Q3 2022 Nov 14, 2022	BUY	$0.49 - $7.65 $58,013 - $905,714	118,394 Added 146.15%	199,400 $90,000
Q2 2022 Aug 12, 2022	BUY	$0.73 - $1.34 $48,841 - $89,654	66,906 Added 474.51%	81,006 $65,000
Q1 2022 May 13, 2022	BUY	$0.89 - $1.85 $12,549 - $26,085	14,100 New	14,100 $19,000
Q3 2020 Nov 13, 2020	SELL	$1.21 - $2.23 $382,481 - $704,903	-316,100 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$0.42 - $1.26 $17,214 - $51,642	40,986 Added 14.9%	316,100 $398,000
Q1 2020 May 14, 2020	SELL	$0.32 - $0.77 $520,365 - $1.25 Million	-1,626,142 Reduced 85.53%	275,114 $132,000
Q4 2019 Feb 13, 2020	BUY	$0.32 - $3.15 $413,594 - $4.07 Million	1,292,484 Added 212.31%	1,901,256 $732,000
Q3 2019 Nov 13, 2019	BUY	$1.79 - $3.33 $202,472 - $376,666	113,113 Added 22.82%	608,772 $1.71 Million
Q2 2019 Aug 12, 2019	BUY	$1.43 - $2.32 $127,211 - $206,384	88,959 Added 21.87%	495,659 $967,000
Q1 2019 May 14, 2019	BUY	$1.46 - $2.33 $299,446 - $477,883	205,100 Added 101.74%	406,700 $939,000
Q4 2018 Feb 13, 2019	BUY	$1.07 - $1.63 $215,712 - $328,608	201,600 New	201,600 $262,000

Ticker LPCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,510,800
Market Cap $431M
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.